A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial

Detalles Bibliográficos
Autores principales: Burnett, A K, Hills, R K, Nielsen, O J, Freeman, S, Ali, A, Cahalin, P, Hunter, A, Thomas, I F, Russell, N H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286330/
https://www.ncbi.nlm.nih.gov/pubmed/29875430
http://dx.doi.org/10.1038/s41375-018-0148-3
_version_ 1783379430840729600
author Burnett, A K
Hills, R K
Nielsen, O J
Freeman, S
Ali, A
Cahalin, P
Hunter, A
Thomas, I F
Russell, N H
author_facet Burnett, A K
Hills, R K
Nielsen, O J
Freeman, S
Ali, A
Cahalin, P
Hunter, A
Thomas, I F
Russell, N H
author_sort Burnett, A K
collection PubMed
description
format Online
Article
Text
id pubmed-6286330
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62863302020-03-18 A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial Burnett, A K Hills, R K Nielsen, O J Freeman, S Ali, A Cahalin, P Hunter, A Thomas, I F Russell, N H Leukemia Brief Communication Nature Publishing Group UK 2018-06-06 2018 /pmc/articles/PMC6286330/ /pubmed/29875430 http://dx.doi.org/10.1038/s41375-018-0148-3 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Brief Communication
Burnett, A K
Hills, R K
Nielsen, O J
Freeman, S
Ali, A
Cahalin, P
Hunter, A
Thomas, I F
Russell, N H
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
title A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
title_full A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
title_fullStr A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
title_full_unstemmed A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
title_short A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
title_sort comparison of flag-ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the uk ncri aml17 trial
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286330/
https://www.ncbi.nlm.nih.gov/pubmed/29875430
http://dx.doi.org/10.1038/s41375-018-0148-3
work_keys_str_mv AT burnettak acomparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT hillsrk acomparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT nielsenoj acomparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT freemans acomparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT alia acomparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT cahalinp acomparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT huntera acomparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT thomasif acomparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT russellnh acomparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT burnettak comparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT hillsrk comparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT nielsenoj comparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT freemans comparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT alia comparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT cahalinp comparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT huntera comparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT thomasif comparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial
AT russellnh comparisonofflagidaanddaunorubicincombinedwithclofarabineinhighriskacutemyeloidleukaemiadatafromtheukncriaml17trial

Ejemplares similares